Evidence of meeting #38 for Health in the 45th Parliament, 1st session. (The original version is on Parliament’s site, as are the minutes.) The winning word was addiction.

A video is available from Parliament.

On the agenda

Members speaking

Before the committee

Azar  Physician, As an Individual
Kaiser  Deputy Medical Director, Direction régionale de santé publique de Montréal
Nickie Mathew  Addiction Psychiatrist, As an Individual
Julian M. Somers  Clinical Psychologist and Full Professor, As an Individual
Merasty  Minister of Self Determination and Self Government, Métis Nation-Saskatchewan
Fullerton-Trotchie  Minister of Health, Mental Health and Addictions, Métis Nation-Saskatchewan

The Chair Liberal Sukh Dhaliwal

I call this meeting to order.

Welcome to meeting number 38 of the House of Commons Standing Committee on Health.

Today's meeting is taking place in a hybrid format, pursuant to the Standing Orders.

I would like to remind participants of the following points: First, please wait until I recognize you by name before speaking. For those participants who are participating by video conference, click on the microphone icon to activate your mic, and please mute yourself when you are not speaking. At the bottom of your screen, you can select the appropriate channel for interpretation—floor audio, English or French.

For members in the room, if you wish to speak, please raise your hand. For members on Zoom, please use the “raise hand” function.

I will give a reminder that all comments should be addressed through the chair. The clerk and I will manage the speaking order as best we can, and we appreciate your patience and understanding in this regard.

Before I go further, because I always forget, I would like to thank the clerk, the analysts, our interpreters—of course—our technical staff, our support staff, and of course the support staff from the honourable members' offices for the work they do behind the scenes to get this committee going.

With that, I'm going to go to the topic.

Doug Eyolfson Liberal Winnipeg West, MB

Mr. Chair, I have a point of order.

Mr. Chair, during the first round of questions to MP Blaine Calkins at our October 7 meeting, I said, “If someone was taking the anticoagulant warfarin to prevent strokes and certain conditions, if they take vitamin D, it counteracts that and gives an increased risk of stroke. In fact, when I'm practising medicine, vitamin D is actually the treatment of choice for someone who comes in and their blood is too thin due to too much warfarin.”

I incorrectly said “vitamin D” when I should have said “vitamin K”, and I would like to officially correct the record.

The Chair Liberal Sukh Dhaliwal

Do I have unanimous consent?

Some hon. members

Agreed.

Doug Eyolfson Liberal Winnipeg West, MB

Thank you, Chair. I will supply a copy of the paragraph and how it should be corrected to the clerk.

The Chair Liberal Sukh Dhaliwal

Thank you.

Doug Eyolfson Liberal Winnipeg West, MB

Thank you very much, and I'd like to thank all the members for their help.

The Chair Liberal Sukh Dhaliwal

Thank you, Dr. Eyolfson.

Pursuant to the motion adopted on Tuesday, September 23, 2025, the committee will resume its study on the opioid epidemic and toxic drug crisis in Canada.

I would now like to welcome our witnesses for the first hour.

We have, by video conference, Dr. Azar. He is appearing as an individual. Dr. Azar, welcome to the meeting.

We also have Dr. Kaiser, deputy medical director of the Montreal regional public health department. Dr. Kaiser, welcome to the committee.

I would like to remind witnesses that committee members may ask questions in either French or English. If you need interpretation, please take a moment now to prepare your earpiece and select the listening channel you need in advance in order to take full advantage of the time allotted for questions and answers.

To the witnesses, please keep an eye on the honourable member who is asking the question. As soon as the honourable member raises a hand, I would like you to stop speaking, because it is the member's time. I don't want to interpret, and we want to make it smooth for the interpreters.

With that, each organization has five minutes for opening remarks. We will give the floor to Dr. Azar.

Dr. Azar, go ahead for five minutes, please.

Pouya Azar Physician, As an Individual

Thank you very much for the invitation and for the opportunity to speak with the committee today.

My name is Dr. Pouya Azar. I am a clinician scientist specializing in addiction psychiatry and pain medicine, so I divide my time between clinical care and research. Clinically, I work in the emergency department, where I care for people presenting with pain and addiction-related concerns. The other half of my time is devoted to research through my professorship at the University of British Columbia. My program focuses on developing practical clinical tools to address the drug poisoning crisis, particularly the challenges created by fentanyl.

As a society, we look at the overdose crisis, at the lives lost and the harms visible on the streets in so many Canadian cities, and we have trouble seeing a way out.

I'm here to provide a message of hope. My career has given me a perspective shaped by two very different periods in addiction medicine. I practised during the heroin era, before fentanyl became widespread, and I have seen first-hand how fentanyl changed clinical practice and contributed to a public health emergency. Fentanyl is a very different drug from heroin and prescription opioids. It is far more potent than morphine, and its effects on the body differ in important ways from those of heroin.

As fentanyl became more prevalent, the treatment approaches and protocols we had relied on became less effective for many patients. The evidence we had was increasingly difficult to apply. In practice, we found ourselves facing an evidence gap at a time when more and more people were dying from drug poisoning. That clinical need led me to build a research program focused on developing and evaluating treatment protocols specifically for people who use fentanyl.

Our approach is grounded in pharmacology and evidence. We need treatments that reflect the realities of fentanyl use and the needs of patients in front of us. Unfortunately, that approach is not yet consistently reflected in the clinical practice across North America. Current guidelines have not kept pace with the changes in the drug supply or with what we are seeing in patients. We need to update our treatments and strengthen the evidence behind them.

We cannot expect better outcomes if we continue relying on approaches that are not working well for the people we are trying to treat. We have seen the consequences of policy and practice that do not adequately account for evidence. In British Columbia, the prescription of pharmaceutical opioids through the safer supply program was intended to reduce people's exposure to the illicit drug supply.

My colleagues and I raised concerns that this approach was not sufficiently supported by pharmacology, or by the broader evidence on opioid exposure and opioid-related harms. In our clinical work, we also saw concerns about diversion, including prescription opioids reaching people who were not the intended recipients. This included children and adolescents developing opioid addiction. The provincial government ultimately ended the unwitnessed component of this program.

Now, please allow me to be clear. Medication is only a first step. Addiction is a biopsychosocial condition. Medication can be essential, but it cannot address addiction on its own. Effective care must also respond to the social and environmental conditions people face, as well as co-occurring mental health concerns. If we want treatment to work, we need to support people with the full range of care and services that recovery requires.

Now, I do want to close with a message of hope. Opioid use disorder is treatable: Recovery is possible. We have developed more effective treatment approaches designed for people who use fentanyl, and continued research can help us improve them. Funding is urgently needed to continue developing, evaluating and implementing these treatment approaches to support recovery and save lives. An evidence-based approach gives us a real opportunity to reduce harm and help people who enter and remain in treatment.

Thank you. I'm happy to take questions.

The Chair Liberal Sukh Dhaliwal

Thank you. That was perfect timing.

Now we will go to Dr. Kaiser for five minutes. Please go ahead.

David Kaiser Deputy Medical Director, Direction régionale de santé publique de Montréal

Good afternoon. Thank you for inviting me to speak to the committee today.

As you can see in the notice of meeting, I am a public health doctor, deputy medical director of the Direction régionale de santé publique de Montréal and director of the residency training program at McGill University, where I've been working to implement a trauma-informed approach since 2023. I was part of the front line public health response to COVID‑19, and since 2022, I've been in charge of our public health emergency preparedness office.

In preparation for today's meeting, I reviewed the work the committee has been doing since 2023 and the input the committee has heard from experts and witnesses. Many of them are well-respected colleagues of mine in the public health field. I'll do my best not to repeat comments or figures you've heard pertaining to areas we are already working to address.

It is clear from the witnesses that no single approach can solve the crisis. The response calls for a range of simultaneous strategies. They need to be implemented in a structured and coordinated way tailored to the local community, and subject to assessment. It's a shared responsibility.

I've spent the past few months meeting with those who organize or use supervised consumption services, or who live near those sites or in neighbourhoods affected by the crisis. I want to share some of the things that stand out to me.

I'll start with a few figures. During the first half of 2026, carfentanil came on the scene in Montreal, adding to a host of adulterants in the substances being used. Between 40 and 50 overdoses a week are reported by our services, more than 500 naloxone kits are handed out weekly, and paramedics intervened 1,000 times in the first six months of the year. That is equivalent to what we saw in all of 2025. The strain on services is intense and unrelenting.

As we address the deaths, we have to recognize how widespread the suffering is. To keep people alive, and ensure the well-being and dignity of those already using, we need to expand service access to match the scale of the crisis, and those services need to be permanent and transformative.

It's not right that in October, we're still waiting for core funding in Montreal to help with shelters and support people experiencing homelessness. It's not right that agencies have to beg for money and fill out all kinds of forms to renew their exemptions, when they could be spending that time saving lives.

The crisis is complex and goes well beyond opioid consumption, as you know. It requires foresight, agility and great flexibility in adapting to local realities. To respond to the crisis, front line agencies need to be able to rely on tailored, long-term funding and assistance based on trust. The illicit drug market is so volatile that we need a system to effectively monitor red flags, and that requires all levels of government and those on the ground to share data.

We also need to significantly increase our focus on prevention. I'll give you a few figures for Quebec. A third of young people who come into contact with the child welfare system and nearly half of those who stay in youth centres end up on the street. In Montreal, one in five people who die of an overdose is experiencing homelessness. Lastly, 13%—or one in seven—of those experiencing visible homelessness identify as indigenous, and most report having substance use issues.

The Public Health Agency of Canada already recommends a trauma- and violence-informed approach. That means that our practices and organizations have to change, but so does the way we design our systems.

Prevention means addressing the intersection of crisis factors within a whole-of-government or health-in-all-policies approach. That includes addressing the right to adapted housing, homelessness, mental health, and the education, prison and justice systems. We need to respond to the acute phase of the crisis and work on prevention at the same time.

In closing, I want to recognize the work this committee has done. This is a social challenge we face collectively. Behind the overdose deaths are people, stories—some of which you've heard—families and communities. The challenges are complex, but the resources, limited.

Every single one of us is working hard. The intention is noble, but one thing is clear: While we look for an answer, the right answer, the deaths and suffering continue.

I'd like to leave you with three recommendations to advance this effort, and address the needs of those who use, communities and all stakeholders. One, secure funding and empower community resources. Two, coordinate efforts across sectors and evaluate them using codeveloped indicators. Three, increase support for community-based research and ongoing shared learning.

The pandemic taught us that we can do things differently. We didn't wait for all the answers to address what we did know. We were able to work together as new information emerged. Let's apply the same logic here.

Thank you again for inviting me. I'd be happy to answer the committee's questions.

The Chair Liberal Sukh Dhaliwal

Thank you very much. That was perfect timing.

Before I go to the members of Parliament, honourable members, if you can mention who your question is for, either Dr. Azar or Dr. Kaiser, it will make it easier for them to answer.

With that, I'm going to MP Konanz for a six-minute round. Please go ahead.

4:45 p.m.

Conservative

Helena Konanz Conservative Similkameen—South Okanagan—West Kootenay, BC

Thank you, Chair.

First I'd like to thank our witnesses for volunteering their time here to speak with us about what I believe is one of the most pressing health issues in our country, which is the continued tragedy of opioid addiction and overdoses. All of Canada has seen this suffering, and my home province of British Columbia has been at the epicentre.

There is almost no family in my province that has not lost a friend or family member to opioid addiction or does not know someone who has lost someone to a deadly overdose. My province is still in crisis. In the communities I represent, we still see people suffering and people dying.

First responders have said that overdose rates in my hometown of Penticton increased by 500% in the first quarter of 2026, compared to the first quarter of 2025. Interior Health has just issued a Kootenay-wide drug alert because of an increase in contaminated fentanyl overdoses. Things do not seem to be getting better.

Worst of all is that treatment and recovery are not available to those who are suffering. If an addict from B.C. walked into this room right now and told us, “I want help. I want to go back to my family”, I've been told that they could face up to a two-year waiting period for a detox or treatment bed if they're from the communities—if they're from my riding—and these treatment beds would be nowhere near their home.

My first question is for Dr. Azar.

Thank you for your message of hope. When I've questioned the Liberals about the policies they've pursued on the opioid crisis—for example, the drug decriminalization pilot that only B.C. was subjected to, the great experiment—I've tried to get clear answers. I'm not getting them. When I asked Health Canada officials whether they viewed the decriminalization pilot as successful, they said it would need a five-year review to answer that question.

Dr. Azar, what do you think of the decriminalization experiment in B.C.? Do you think it was successful in tackling the opioid crisis?

4:50 p.m.

Physician, As an Individual

Pouya Azar

Well, I have yet to see the official data. What I can say is that the numbers of overdoses or drug poisoning deaths in British Columbia were not significantly reduced as compared to the rest of North America. If that remains a measure of success, it appears that it was not.

Having said that, I think we need to see the data, and I think real research needs to be done with the data to definitively provide an answer.

4:50 p.m.

Conservative

Helena Konanz Conservative Similkameen—South Okanagan—West Kootenay, BC

Dr. Azar, why do you think that it would take five years to get that data?

4:50 p.m.

Physician, As an Individual

Pouya Azar

That's a good question, and I don't know. I'm not sure where that figure came from. I can't answer that question, unfortunately.

4:50 p.m.

Conservative

Helena Konanz Conservative Similkameen—South Okanagan—West Kootenay, BC

Dr. Azar, you're a specialist in rapid opioid agonist treatment protocols, which avoid a so-called “safe supply” approach in favour of methods that look for medical recovery and abstinence-based pathways. We have that in our treatment centre in Discovery House in Penticton, which is having good results.

Are agonist-based research and treatment methods currently being sufficiently funded by provincial and federal governments?

4:50 p.m.

Physician, As an Individual

Pouya Azar

I can tell you that if I apply today for a grant to support my research, it'll be upwards of two years before I see the money and can implement that study. We don't have that kind of time. The illicit drug market is changing rapidly, from month to month even, so we need to move quickly.

Our lab has relied on philanthropy as a means of support, and that's allowed us to move very quickly and develop treatment protocols that address the needs of our patients today.

To answer your question, funding is needed, and it's needed rapidly.

Helena Konanz Conservative Similkameen—South Okanagan—West Kootenay, BC

You agree that five years is too long in this tragic situation.

We recently had a ruling in British Columbia that stayed drug trafficking convictions of the Drug User Liberation Front. The judge said that it was unconstitutional to limit the distribution of illegally purchased, improperly stored, illegally sold opioids if it did not negatively impact the community or public safety.

Do you think drug trafficking of opioids impacts communities or public safety, and does it worsen the drug crisis we see in B.C.?

4:50 p.m.

Physician, As an Individual

Pouya Azar

The evidence we have is that the more opioids we have available in society, the higher the rates of opioid use disorder will be and the higher the rates of overdose death or death by drug poisoning will be.

Addressing this crisis takes a multipronged approach. One of those approaches would be enforcement, but that has to be equated with harm reduction, treatment, etc. However, the evidence that I'm familiar with says that the more opioids we have, the more opioid use disorder we will have and the more overdose deaths we will have.

The Chair Liberal Sukh Dhaliwal

Thank you very much.

We'll go to Dr. Jaczek for six minutes. Please go ahead.

Helena Jaczek Liberal Markham—Stouffville, ON

Thank you, Chair, and thank you again to the witnesses.

Dr. Azar, you've described the changes that you've seen in terms of the opioid crisis—the move from heroin as the primary cause of addiction to now, when fentanyl-contaminated products seem to cause the most urgent need for effective treatment. Thank you for describing that.

Over time, we have seen—and apparently we have some data here—that Canada's opioid-related deaths have been decreasing in the past couple of years. Deaths decreased by 23% in 2025 compared with 2024 and by 10% in 2026 compared to 2025.

In your opinion, what factors have contributed to this decline?

4:55 p.m.

Physician, As an Individual

Pouya Azar

The data that I am familiar with speaks to overdose death rates going down across North America. They're going down in British Columbia, in Texas, in the United States and on the east coast of Canada. There remains to be a report that definitively describes the reasons this occurred. I don't believe we can attribute it to any one intervention.

I suspect that much of it is related to the composition of the illicit drug supply. We've seen some decreased percentage of fentanyl and fentanyl analogs. We've seen an increase in adulterants, such as alpha-2 agonists, benzodiazepines, etc., so we've seen a drug supply that may be less potent in causing opioid-related side effects, including respiratory depression and death. However, I don't believe that's the only answer. It's a potential hypothesis.

Again, I want to underscore that this is something consistent that has occurred across North America.

Helena Jaczek Liberal Markham—Stouffville, ON

Of course, we shouldn't just look at the death situation—in other words, the lethality of what is being used. We need to look, as Dr. Kaiser has said, at the concomitant problems.

Perhaps, Dr. Kaiser, you could talk a bit more about what you've seen in terms of homelessness and what the federal government could do in a practical sense to assist on the prevention side of things and with potential treatment for those with addiction.

4:55 p.m.

Deputy Medical Director, Direction régionale de santé publique de Montréal

David Kaiser

How many hours do I have?

Briefly, I think there are a couple of things.

One is that we can take prevention across the lifespan. We know that adverse childhood experiences are linked to substance use, homelessness and mental health issues. When we're looking at what the federal government can do, we know that child care, prenatal and pregnancy care, and quality education are prevention. It's not for 50 years from now; it's for a cohort that will be entering adolescence 10 years from now. I think that's really important. The federal government has a role to play in our young people's structural conditions.

Second is housing. With the pandemic and the changes in the drug supply, we see the overlap clearly. I mentioned the mortality statistics, but we also see it in the people who are using our harm reduction sites. When you're in the streets, you're not sleeping, you're subjected to violence and you're much more likely to have your mental health problem aggravated and your consumption aggravated.

For sure, we need adapted housing. We've had a national housing strategy for a couple of years, and there are things that have been updated, but we know that we still need massive increases in adapted housing, including low-rent and off-market housing with mental health supports and supports for people who are using drugs. That's a place where the federal government has a role in terms of the criteria, the indicators that are being set and the financing that's going to the provinces.

The third aspect, coming back to what Dr. Azar said, is our ability to use all of the services we have as entry points into the system. We're having people use harm reduction services. We're having people come to emergency rooms. We're having people access housing supports. All of that should be feeding into the same trajectory, which is to get people stabilized, off the street and into treatment when they're ready.